The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure
Status:
Withdrawn
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The present study will examine the effects of liraglutide treatment during 26 weeks on
several cardiovascular risk factors in patients with prediabetes and end-stage renal disease
(ESRD). The primary objective is to determine the efficacy of the treatment on glucose
tolerance evaluated during a 3h 75g-oral glucose tolerance test (OGTT). Secondary objectives
include various clinical and biochemical cardiovascular and safety parameters.
We hypothesise that treatment with liraglutide can improve glucose tolerance in prediabetic
patients with ESRD by normalizing plasma glucose excursions during an OGTT and ameliorate
other cardiovascular risk factors.
Phase:
Phase 2
Details
Lead Sponsor:
Bo Feldt-Rasmussen
Collaborators:
Novo Nordisk A/S The GCP unit at Copenhagen University Hospital